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Abstract
Tumor cell plasticity is a major obstacle for the cure of malig-
nancies as it makes tumor cells highly adaptable to microenvi-
ronmental changes, enables their phenotype switching among
different forms, and favors the generation of prometastatic tumor
cell subsets. Phenotype switching toward more aggressive forms
involves different functional, phenotypic, and morphologic
changes, which are often related to the process known as epithe-
lial–mesenchymal transition (EMT). In this study, we report
natural killer (NK) cells may increase the malignancy of melano-
ma cells by inducing changes relevant to EMT and, more broadly,
to phenotype switching from proliferative to invasive forms. In
coculture, NK cells induced effects on tumor cells similar to those
induced by EMT-promoting cytokines, including upregulation
of stemness and EMT markers, morphologic transition, inhib-
ition of proliferation, and increased capacity for Matrigel inva-
sion. Most changes were dependent on the engagement of
NKp30 or NKG2D and the release of cytokines including IFNg
and TNFa. Moreover, EMT induction also favored escape from
NK-cell attack. Melanoma cells undergoing EMT either increased
NK-protective HLA-I expression on their surface or downregulat-
ed several tumor-recognizing activating receptors on NK cells.
Mass spectrometry–based proteomic analysis revealed in two
different melanoma cell lines a partial overlap between proteo-
mic profiles induced by NK cells or by EMT cytokines, indicating
that various processes or pathways related to tumor progression
are induced by exposure to NK cells.
Significance: NK cells can induce prometastatic properties on
melanoma cells that escape from killing, providing important
clues to improve the efficacy of NK cells in innovative antitumor
therapies. Cancer Res; 78(14); 3913–25. 2018 AACR.
Introduction
Attempts to exploit the natural killer (NK) cell antitumor
potential for the cure ofmalignancies recently have proven highly
promising for the therapy of certain hematologic malignancies,
but have failed so far in solid tumors (1–5). The frustrating results
on solid tumors can be explained, at least in part, by the presence
at the tumor site of a specific microenvironment capable of
interacting with the immune effectors in a complex and still
partially unknown cross-talk, which may have unpredictable
effects on immune-based therapeutic approaches. The tumor
microenvironment can profoundly influence the availability and
the function of different immune cell types, including NK cells
(6, 7). Indeed, various elements present in the tumor site have
been shown to induce downregulation of different activating NK
receptors involved in tumor cell recognition (6, 7), including
NKG2D, DNAM-1, and the natural cytotoxicity receptors (NCR)
NKp30, NKp46, and NKp44 (8).
Moreover, immune cells can participate in the tumor cell
editing, favoring the selection/induction of tumor cells abnor-
mally expressing immune-receptor ligands involved in either
tumor cell recognition (HLA-I molecules and ligands for
NKG2D, DNAM-1, and NCR) or immunoregulatory check-
points (CTLA-4 and PDL-1; 5, 6, 9–13). Recently, it has also
been proposed that certain immune cells present in the tumor
microenvironment (namely MDSCs, macrophages, neutro-
phils, and CD4þ T cells) could even favor tumor progression
by promoting epithelial–mesenchymal transition (EMT;
refs. 14–18).
According to recent viewpoints, in different tumors, including
melanomas, transformed cells would be characterized by a
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remarkable phenotypic and functional plasticity. This plasticity
would enable tumor cells to "switch" from a differentiated,
proliferative, and poorly invasive state to an undifferentiated,
poorly proliferative, and invasive (prometastatic) state (and vice
versa; refs. 19, 20). These views unify in a comprehensive phe-
nomenon, which is termed "phenotype switching," different
aspects and concepts of the tumor cell biology including the
EMT, the generation of cancer stem cells, and the acquisition of
drug or radiotherapy resistance (20, 21). Indeed, depending on
the tumor cell type, the "phenotype switching" often involves
(i) transition toward an undifferentiated/mesenchymal morpho-
logy, accompanied by E- and N-cadherin expression switch and
cytoskeletal modifications; (ii) acquisition of stemness markers
(such as CD166, CD133, and CD271); (iii) proliferation
decrease; and (iv) modulation of key transcription factors such
as SLUG, SNAIL, and SPARC (19, 22–24). In particular, in
melanoma cells, modulation of microphthalmia-associated tran-
scription factor (MITF) appears to play a key role (20).
Various stimuli can favor tumor cell transition including
TGFb and WNT signaling, alteration of receptor Tyr-kinase
pathways, hypoxia, and, as mentioned above, the interaction
with certain immune cell types (14–19). To our knowledge, no
information is available on a possible NK:tumor cell cross-talk
in the context of the tumor cell phenotype switching, although
the EMT could preferentially occur at the tumor borders, where
NK cells have been more frequently localized (6, 18). In this
study, we describe and characterize such NK:tumor cell cross-
talk and provide evidence of the possible paradoxical activity
that NK cells could play in the tumor progression, at least in
certain conditions.
Materials and Methods
Generation of polyclonal NK-cell lines
NK cells from healthy donors were purified from peripheral
blood and cultured on irradiated feeder cells and rhIL2 for 15
to 20 days (see Supplementary Materials and Methods).
Melanoma cell lines, EMT induction, and cocultures
MeDeBO, MeCoP, MeTU, MePA, and MeTA cell lines were
derived from metastatic melanoma resections provided by the
local Cancer Surgery Unit and were described previously (25).
Once established, the primary cell lines were initially expanded
for few passages, phenotypically characterized by FACS, and
frozen in multiple aliquots. For the experiments described in this
study, cells were thawed, tested for mycoplasma by specific PCR,
and used within 30 days. The melanoma cell cultures were
phenotypically characterized and assessed for purity by the anal-
ysis of informative markers including Mel-CAM/CD146, GD2,
and HLA-I. To evaluate EMT/phenotype switch, melanoma
cells were cultured in RPMI1640 10% FCS in 6-well plates to
75% confluence, washed, and cultured in complete medium
plus 100 IU/mL IL2 either in the absence or in the presence of
polyclonal NK cell lines, or in complete medium containing
5 ng/mL TGFb1 þ 10 ng/mL TNFa (EMT cytokines; PeproTech).
After 96 hours, melanoma cells were evaluated by FACS/
microscopy, or in functional assays, or in proteomic analysis.
Coculture melanoma:NK cell ratios were 5:1 (MeDeBO, MeTU,
MePA, MeTA) or 2:1 (MeCoP). When indicated, cocultures were
performed in transwell devices (Corning Incorporated)maintain-
ing the same ratios and culture times.
Flow cytometry and cytolytic assays
Cells were stained with appropriate mAbs, followed, when
needed, by PE-conjugated isotype-specific second reagent
(Southern Biotechnology Associated). For intracellular staining
of fibronectin, MITF, and Ki67, melanoma cells were fixed and
permeabilized using Permeabilization/Fixation Kit (for cyto-
plasmic proteins) or Foxp3/Transcription Factor Fixation/
Permeabilization Kit (for nuclear proteins; eBioscience). Cells
were analyzed by FACSCalibur (Becton Dickinson). For anti-
bodies and soluble NCRs, see Supplementary Materials and
Methods.
Melanoma cell susceptibility and NK-cell killing capability
were evaluated in 4-hour 51Cr-release assays.
Microscopy
Microphotographs were taken using Olympus IX70 micro-
scope equipped with the Hamamatsu ORCA-ER digital camera
(images analyzed by CellR 1.2 Olympus).
Confocal microscopy
Melanoma cells were seeded on glass coverslips and cul-
tured under the indicated conditions. After 4 days, melanoma
cells were washed, fixed, permeabilized, and stained with
Alexa Fluor 488 phalloidin (Molecular Probes) and DAPI
(see Supplementary Materials and Methods).
Matrigel invasion assays
High-density Matrigel (20 mL; 10 mg/mL) with reduced
growth factor content (BD Biosciences) were dropped in
12-well plates. Melanoma cells alone, or pretreated for 72 hours
with EMT cytokines, or cocultured for 72 hours with NK cells
were added in the wells after drop solidification. Melanoma
cells were added to obtain 80% confluence (final volume:
1 mL). NK cells and cytokine stimuli were maintained in
(co-)cultures for 7 days before taking microphotographs.
Statistical analyses
Statistical analyses were performed by Wilcoxon t test or
Mann–Whitney test as indicated in the figure legends (, P 
0.05; , P  0.01; , P  0.001).
Mass spectrometry–based proteomics
Samples were processed by in-Stage Tip protocol (26). Each
digested sample was analyzed by high-resolution LC/MS-MS)
based on Orbitrap technology. The quantification strategy is
based on a label-free approach (LFQ) available in MaxQuant
suite. The proteomics data are subjected to a statistical valida-
tion applying tools developed in Perseus Software (See Sup-
plementary Materials and Methods; ref. 27).
Bioinformatics analysis
The methodology used in this study combines machine
learning approaches (28, 29). In each comparison, proteins
are ranked according to their discriminatory power of the
corresponding phenotype and measured by a combination
of fold change and Fisher ratio. Their predictive accuracy is
established using a series of cross-validation experiments.
Then, using GeneAnalytics software, we identified the path-
ways or the biological processes associated with the protein
list (see Supplementary Materials and Methods).
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IHC analysis
Sections were obtained from formalin-fixed paraffin-embed-
ded tissue blocks of human primary cutaneous melanomas.
Briefly, for IHC, the reaction was revealed using Novolink
Polymer (Leica) or Labelled Polymer HRP (Dako) followed
by DAB (single stainings of E-cadherin, N-cadherin, ZEB1,
ZEB2). For double staining, sections were stained with two
consecutive reactions with primary antibodies, using OptiView
DAB IHC Detection Kit and ultraView Universal Alkaline Phos-
phatase RED Detection Kit (to assess E- or N-cadherin expres-
sion in areas close to or far from CD56þ NK cells) or Mach 4
MR-AP (Biocare Medical), followed by Ferangi Blue (to assess
CD56 and SOX5). The quantification of marker expression
was evaluated as percentage of positive cells or as "H-score."
The H-score was assigned in each area as the sum of the
products of the intensity (0 for negative, 1 for weakly positive,
2 for moderately positive, and 3 for strongly positive) and the
extent of immunoexpression (0%–100%).
Patient studies
For the use of material from the patients, written informed
consent was obtained. The studies were conducted in accordance
with the Declaration of Helsinki and were approved by the local
Institutional Review Boards to WV (WW-IMMUNOCANCERhum,
code NP-906) and to MCM (PR023REG2013).
Results
NK cells promote EMT and phenotype switching in melanoma
cell lines
In order to study the possible effect of NK cells on the tumor
cell phenotype switch, we set up mixed cell coculture experi-
ments using primary polyclonal NK cell lines derived from
healthy donors and 5 melanoma cell lines (MeDeBO, MeCoP,
MeTU, MePA, and MeTA; ref. 25). These melanoma cell lines
were selected on the basis of their different EMT characteristics
at baseline and differential ability to undergo modulation of
their phenotype and/or function in response to EMT-inducing
cytokines (TNFa þ TGFb1; EMT cytokines) (23). Cocultures
were done at low NK:melanoma cell ratios, that is, cell-to-cell
proportions coherent with the generally low NK-cell infiltrate
observed in tumors (6, 9). As controls, melanoma cells were
cultured alone either in the absence of additional stimuli or in
the presence of EMT cytokines. After 72 hours of coculture,
melanoma cells were analyzed by FACS or microscopy for the
expression and/or the distribution of informative markers and
typical EMT proteins.
Thus, we first analyzed the stemness markers CD271 and
CD166, the transcription factor MITF, and the G protein–coupled
receptor GPR56. As also mentioned above, MITF expression
decrease is a hallmark of the phenotype switch in melanoma,
while GPR56 expression has been inversely correlated with the
acquisition of prometastatic properties (30). As shown in Fig. 1A,
upon exposure toNK cells,mostmelanoma cell lines significantly
increased the expression of CD271 and CD166 and reduced the
expression of MITF and GPR56. Specifically, MeDeBO, MeCoP,
and MeTUmodified, at various extents, all the analyzed markers,
whereas MePA and MeTA showed changes only in CD271 and
MITF, respectively. Noteworthy, the effect of coculture with NK
cells was similar to (or even more pronounced than) that of EMT
cytokines in all the analyzed melanoma cell lines.
We then evaluated typical features of the EMT such as
cadherin switch (concomitant downregulation of E-cadherin
and upregulation of N-cadherin expression), fibronectin expres-
sion, F-actin filament reorganization, and morphologic
changes. Among the cell lines analyzed, MeDeBO and MeCoP
cells showed clearest EMT-related changes in response to both
NK and cytokine stimulation, whereas MePA and MeTA cells,
expressing EMT-related features at baseline, poorly modified
their phenotype (Fig. 1B; Supplementary Fig. S1). MeDeBO cells
(which highly expressed E-cadherin at baseline) showed cad-
herin switch, fibronectin expression increases, and cytoskeleton
reorganization, as indicated by the generation of F-actin stress
fibers, whereas MeCoP cells, besides increasing F-actin reorga-
nization, acquired a clear spindle-shaped morphology typical
of EMT.
We next analyzed Ki67 expression, a reliablemarker to evaluate
cell growth. As shown in Fig. 1C, inhibition of proliferation in
MeDeBO and MeCoP occurred after coculture with NK cells,
further supporting thenotion thatNK cellsmay induce phenotype
switching.
Finally, we analyzed whether NK cells had any effect on the
invasive capability of melanoma cells. To this end, melanoma
cells were assessed for the capacity to enter and move through
Matrigel spheres. Among the analyzed cell lines, MeCoP cells
showed invasive capabilities after induction of EMT by NK cocul-
ture or EMT cytokines. Thus, spindle-shaped MeCoP cells
acquired a bundle organization that favored the invasion of the
Matrigel sphere (Fig. 1D; Supplementary Fig. S2).
Because the process of EMT, and in particular the down-
regulation of E-cadherin, can be regulated by specific transcrip-
tional factors, we assessed the effects of NK cells on SNAIL,
SLUG, TWIST, and ZEB2 expression in MeDeBo cells. As shown
in Supplementary Fig. S3A, NK cells induced increased expres-
sion of SLUG and ZEB2 in MeDeBO cells after 24 and 48 hours
of coculture. This finding is in line with the progressive
decrease of E-cadherin expression in MeDeBO cells (Supple-
mentary Fig. S3B).
Altogether, our experiments indicate that NK cells are capable
of inducing different changes in melanoma cells compatible with
EMT and phenotype switching.
NK-induced melanoma phenotype switching/EMT depends
on cell-to-cell interaction and release of IFNg and TNFa
In order to define the mechanisms underlying the NK cell–
mediated induction of the phenotype switching in melanoma
cells, we performed coculture experiments in transwells (out-
lined in Supplementary Fig. S4). We chose the representative
cell lines, MeDeBO and MeCoP, and analyzed parameters
suitable for evaluating the effect of NK cells. In particular,
MeDeBO cells were analyzed for the expression of E-cadherin,
CD271, MITF, GPR56, and Ki67, whereas MeCoP cells were
assessed essentially for their morphology. As shown in Fig. 2A
and B, MeDeBo and MeCoP cells underwent phenotypic or
morphologic changes when NK and melanoma cells were cul-
tured in contact but not when cocultures were performed in
transwell (i.e., NK and melanoma cells were cultured in the
upper and lower chamber, respectively, TW). On the other hand,
the phenotype switching (or the EMT) was induced in melano-
ma cells alone in the lower chamber when NK:melanoma
cocultures were set up in the upper chamber of the transwell
(TW/w). These experiments indicate that NK–tumor cell contact
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Figure 1.
NK cells can induce traits of the phenotype switch in melanoma cells. The indicated melanoma cell lines were cultured alone (Nil), exposed to EMT
cytokines, or cocultured with NK cells, and analyzed by FACS or microscopy to evaluate. A, Informative markers of malignancy and/or stemness. B, EMT
markers and morphology, and F-actin distribution (green). Scale bars, 50 mm. C, Ki67 expression. D, Capability of invading a Matrigel droplet (the border is
indicated by the white dashed line). Scale bars, 200 mm. Data from FACS analyses are represented by histograms as mean fluorescence intensity (MFI)
mean þ SEM of at least four independent experiments. FACS profiles from a representative experiment are also shown in A and B. Isotype control
(gray profiles), melanoma cells cultured alone (gray-filled profiles), with cytokines (black profiles), with NK cells (dashed profiles). Statistical analyses
were performed by Wilcoxon t test.
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is required for inducing melanoma cell modification and that
most of the effects induced by NK cells are mediated by soluble
factors released following such cell-to-cell interaction.
In order to molecularly characterize the nature of the
NK:melanoma cell interactions, we performed coculture experi-
ments in the presence of blocking antibodies directed to major
activating NK receptors or NK-derived cytokines. As shown
in Fig. 2C, anti-IFNg Abs and, to a minor extent, anti-TNFa
Abs inhibited the effect of NK cells on CD271 expression in




engagement of NK triggering
receptors, and cytokine release. A and
B,Melanoma cells were cultured alone
(Nil), with NK cells (NK), with NK cells
in transwell devices. The upper
chamber of transwell was loaded with
NK cells (TW) or with NKþmelanoma
cells (TW/w). Informative markers
(MeDeBO) or morphology changes
(MeCoP) were analyzed by FACS or
microscopy. Scale bars, 100 mm. The
control MeCoP cellswere also cultured
in the presence of EMT cytokines.
Histograms represent mean
fluorescence intensity (MFI) mean þ
SEM of 6 independent experiments.
C andD,Melanoma cells were cultured
alone (Nil), with NK cells (NK), with NK
cells in the presence of blocking mAbs
to the indicated receptors or
cytokines. Informative markers
(MeDeBO) or morphology changes
(MeCoP) were analyzed by FACS or
microscopy. Scale bars, 100 mm. In C,
the expression changes induced in the
various conditions are calculated as
mean fluorescence intensity ratio to
Nil condition (meanþ SEMof at least 5
experiments is shown). Statistically
significant differences to the control
Ab "isotype" condition are indicated.
The shady areas highlight the extent of
NK-induced changes and potential
phenotype restoration by blocking
mAbs. Statistical analyses were
performed by Wilcoxon t test.
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inhibitory trend toward the NK-induced effect on E-cadherin.
Significant inhibitory effects were obtained also by blocking
different activating receptors, with maximal effects achieved
upon NKp30 and NKG2D blockage. NKp30 and NKG2D
blockage also appeared to inhibit the NK-mediated effect on
melanoma proliferation (although without reaching statistical
significance; Fig. 2C, see Ki67 expression). Nevertheless, also
NKp44, DNAM-1, and NKp46 receptors could contribute to the
NK:melanoma interaction as their combined blockage resulted
in an inhibitory effect comparable with that obtained by
NKp30 masking (Supplementary Fig. S5A). Similarly, various
blocking Abs also showed an effect in the MeCoP:NK cell
coculture. Thus, anti-IFNg , anti-NKp30, anti-NKp46, anti-
NKG2D, as well as anti–DNAM-1 Abs efficiently counteracted
the NK-induced morphologic transition of MeCoP cells, where-
as anti-NKp44 and anti-TNFa Abs showed minor effects (Fig.
2D). Finally, we also analyzed whether TGFb could be involved
in the NK-induced effect on melanoma cells, because such
EMT-inducing cytokine may be either produced by tumor cells
or induced in cocultures. As shown in Supplementary Fig. S5B
and in Fig. 2D, anti-TGFb–blocking Abs did not interfere with
the phenotypic or morphologic changes induced by NK cells
in MeDeBO and MeCoP cells.
In conclusion, our results indicate that the induction of
tumor phenotype switching/EMT by NK cells is primarily
sustained by IFNg (and partly by TNFa), that is, cytokines that
are released upon NK:melanoma cell interaction and engage-
ment of activating receptors.
Effect of phenotype switching/EMT on the NK:melanoma
cell cross-talk
We then analyzed whether undergoing a phenotype switch
modifies melanoma cell susceptibility to NK cell–mediated
attack, or their ability to suppress NK-cell activity.
The phenotype switching/EMT on MeDeBO and MeCoP
cells, induced either by exposure to EMT cytokines or by cell
coculture with NK cells, did not substantially modify the
surface expression of NKG2D or DNAM-1 ligands, nor did it
modify the binding of the soluble NCRs (to their ligands at the
tumor cell surface; Supplementary Fig. S6). We also assessed
the expression of PD-L1, as this suppressive molecule can be
induced during EMT on breast cancer cells (13). As shown in
Supplementary Fig. S6, exposure to both cytokine and NK cells
resulted in a slight induction of PD-L1 expression in MeCoP
cells, whereas it was ineffective in MeDeBO cells. On the other
hand, MeCoP cells evidencing phenotype switch showed a
marked HLA-I surface expression increase accompanied
by increased resistance to NK-cell killing activity (Fig. 3A and
B). HLA-I masking by specific mAbs completely restored the
susceptibility of "cocultured" MeCoP cells to NK cell–mediated
killing, an effect that was incomplete on cytokine-treated mel-
anoma cells (Fig. 3C), suggesting that, besides HLA-I upregula-
tion, additional mechanism of resistance may be induced by
EMT cytokines. MeDeBO cells lacked surface HLA-I molecules.
Accordingly, they did not show any modification of HLA-I
expression and did not modify their susceptibility to NK
cell–mediated killing (Fig. 3D and E). Exposure to EMT cyto-
kines or coculture with NK cells led to HLA-I upregulation
also on MePA, MeTU, and MeTA cells, despite in these cases,
the effects were less statistically significant (Supplementary
Fig. S7). We also assessed whether exposure to NK cells could
increase resistance of MeCoP and MeDeBO cells to therapeutic
treatments such as cytotoxic drugs or g-radiation. As shown
in Supplementary Fig. S8, NK cells did not modify the sus-
ceptibility of melanoma cells to taxol, while increased resist-
ance to g-radiation in MeCoP (although without reaching
statistical significance).
In order to assess the effect of EMT on the immunosuppres-
sive capability of melanoma cells, MeCoP and MeDeBO cells
were exposed to EMT cytokines to induce phenotype switching
(EMT melanoma cells), and, afterwards, cocultured with NK
cells for 3 days. As TGFb can affect both NK-cell function and
phenotype, EMT melanoma cells were extensively washed
before starting coculture. NK cells from cocultures were then
analyzed for the expression of major activating receptors. As
shown in Fig. 4A, melanoma cells were able to induce down-
regulation of NKp30, NKG2D, and DNAM-1 on NK cells. The
difference between untreated and EMT melanoma cells in
decreasing NCR expression was statistically significant in the
case of MeDeBo cells. Thus, NK cells exposed to MeDeBO cells
were also tested in a cytolytic assay. As shown in Fig. 4B, NK cells
conditioned by EMT-MeDeBO cells showed maximal inhibition
of their ability to kill melanoma cells as compared with NK cells
exposed to MeDeBO cells or cultured alone. Because induction
of immune checkpoint receptors on NK cells has been associated
with tumor progression (12, 31), we also assessed whether EMT
melanoma cells could influence TIM-3 and PD-1 expression on
NK cells. As shown in Fig. 4A, both melanoma cell lines induced
little fluctuations of TIM-3 expression on NK cells. In particular,
exposure to EMT-MeDeBO cells resulted in slight, but not
significant increase of TIM-3 expression. PD-1 expression was
not induced in either the analyzed conditions.
Thus, the phenotype switch/EMT can favor the escape to NK-
cell antitumor activity by enabling tumor cells to express higher
levels of HLA-I molecules and to increase their ability to target
activating receptors on NK cells.
Analysis of proteomic profiles induced by NK cells on
MeCoP and MeDeBO cells
The above functional and phenotypic data indicate that NK
cells can induce, in melanoma cells, traits of increased malig-
nancy that are hallmarks of phenotype switch or EMT. To gain
further insight on this activity and acquire a more comprehen-
sive characterization of the NK cell–mediated effect on mela-
noma cells, we analyzed the proteomic changes induced by NK
cells or by EMT cytokines on MeCoP and MeDeBO cell lines.
High-resolution mass spectrometry analysis of cell lysates
led to the definition of about 5,000 proteins for each cell line
(in each individual experimental condition). The Spearman
rank correlation indicated an acceptable reproducibility
among the analyzed biological replicates (average coefficients
> 0.92 for each condition in both cell lines; Supplementary
Fig. S9A). As shown by the Venn diagrams (Fig. 5A), exposure
to NK cells or to EMT cytokines, respectively, induced the
modulation of 183 or 268 proteins in MeCoP cells, and
1,466 or 2,957 proteins in MeDeBo cells (T test false discovery
rate ¼ 0.05, S0 ¼ 0.1; also see the protein lists in Supplemen-
tary Table S1). Thus, the number of differentially expressed
proteins greatly differed between the two cell lines, suggesting
a potential, marked variability among melanoma cells in the
response to stimuli and, specifically, to NK cells. In spite of
this variability, a consistent part of the proteins that were
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modulated upon NK-cell exposure was also influenced by
cytokine treatment in both cell lines analyzed (49% and
72% of NK-modulated proteins in MeCoP and MeDeBo,
respectively). In addition, the unsupervised hierarchical clus-
tering analysis of differentially expressed proteins indicated
that NK cells and cytokines often induced concordant protein
modulation (Fig. 5B; Supplementary Fig. S9B).
To extensively define the functional networks and the poten-
tial effects induced by NK cells, we investigated whether the NK-
modulated proteins could be enriched in specific biological
processes or pathways. Thus, proteins clustered according to
their expression values as up- or downregulated were analyzed
using GeneAnalytic platform (see Materials and Methods). In
either NK-conditioned melanoma cell line, both up- and down-
regulated protein clusters showed significant enrichment in a
sizable number of biological processes or pathways (collective-
ly referred to as entities; Supplementary Tables S2 and S3). As it
may be expected, in both cell lines, the upregulated protein
clusters showed a great enrichment in entities related to cell
death and IFNg-dependent response, confirming the major role
of classical NK-cell functions in the NK:melanoma cell cross-
talk (Fig. 5C; Supplementary Tables S2 and S3). On the other
hand, upregulated protein clusters also showed enrichment in a
large number of entities related to tumor cell invasiveness and
dissemination (i.e., cell adhesion, morphology, and motility),
induction of classic oncogenic pathways or EMT (including
SMAD and ERK signaling, TGFb pathway, VEGF signaling,
developmental biology), or response to stress. Moreover,
downregulated protein clusters were enriched in entities related
to oncogene suppression, cell proliferation, and metabolism
(Fig. 5C; Supplementary Tables S2 and S3).
In conclusion, the proteomic analysis indicates that NK
cells can activate at least part of the EMT cytokine–induced
programs in melanoma cells. Importantly, they can induce
melanoma cells to modify the expression of a wide range of
proteins involved in diverse aspects of tumor cell biology, and
to acquire proteomic profiles compatible with the switching
toward an undifferentiated, poorly proliferative, and invasive
(prometastatic) state.
Effects of NK cells at the tumor site
We next analyzed whether NK cells could induce EMT-related
effects also at the tumor site. To this end, we assessed by IHC a
panel of primary melanoma lesions characterized by either
poor or rich NK-cell infiltrate (NK-poor samples: <10 NK
cells/mm2; NK-rich samples: >30 NK cells/mm2). In particular,
samples were assessed for the expression of E- and N-cadherin,
and ZEB1, ZEB2, and SLUG transcription factors. SLUG was
excluded from the analysis due to poor staining quality of
formalin-fixed sections for this marker. The analysis of the
other markers revealed that E-cadherin expression was signif-
icantly reduced in the group of NK-rich samples, whereas
N-cadherin, ZEB1, and ZEB2 expression showed a trend to
increase (Fig. 6A). Remarkably, although only E-cadherin mod-
ulation reached statistical significance, the expression changes
of the four analyzed markers were all in the specific direction
of EMT. A more detailed analysis revealed that cadherin expres-
sion could be heterogeneously distributed within a single
sample. In Fig. 6B, both an NK-rich and an NK-poor case show
areas of complete cadherin switch, near the NK-cell infiltrate,
and areas (devoid of NK cells) with an opposite cadherin
pattern. On their complex, these data suggest that the presence
Figure 3.
Effect of EMT on melanoma cell susceptibility to NK lysis. The indicated melanoma cell lines were cultured alone (Nil), with EMT cytokines (cyt), or NK cells
(NK), and then analyzed. A and D, For HLA-I expression by FACS. B, C, and E, For susceptibility to NK-cell lysis in cytolytic assays. In C, the effect of
HLA-I masking mAbs is also assessed. Data from FACS analyses are represented by histograms as mean fluorescence intensity (MFI) mean þ SEM of at least 5
independent experiments. FACS profiles from a representative experiment are also shown. Isotype control (gray profiles), melanoma cells cultured alone
(gray-filled profiles), with cytokines (black profiles), with NK cells (dashed profiles). Data from cytolytic assays represent the meanþ SEM of 6 samples pooled
from three independent experiments. In B, statistically significant differences to the "Nil" condition refer to both NK- and cyt-conditioned targets.
Statistical analyses were performed by Wilcoxon t test (A and D) and Mann–Whitney test (B, C, and E).
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and the proximity of the NK-cell infiltrate may favor the
EMT. We also found samples showing rather homogeneous
N- or E-cadherin expression, independent on the NK-cell local-
ization. In these cases, the prevalence of various factors known
to affect EMT (i.e., cytokines, hypoxia, stromal cells, or other
immune cells) may have masked the specific effect of NK cells.
To further dissect the effect of NK cells on EMT, we selected
a sample showing heterogeneous distribution of NK cells
and cadherins and quantified E- and N-cadherin expression
in the areas close to or distant from NK-cell infiltrate (see an
example in Supplementary Fig. S10). This quantification was
done by calculating the H-score for each of the areas included
in the "close" or "far" group (see Supplementary Materials
and Methods). As shown in Fig. 6C, the areas close to NK
cells showed a statistically significant lower expression of
E-cadherin and higher expression of N-cadherin as compared
with areas distant from NK cells. These data definitely indicate
that, at least in certain cases, NK cells can influence the EMT at
the tumor site.
Discussion
This study provides the first experimental evidence that NK
cells can induce the phenotype switching of melanoma cells to
an undifferentiated, poorly proliferative, proinvasive state. We
show that the presence of NK cells in coculture experiments can
induce on melanoma cells increased expression of stemness
markers, E- and N-cadherin switch, cytoskeletal and morpho-
logic rearrangements, reduced tumor proliferation rates, and
also, in one melanoma cell line, increased invasiveness. More-
over, the analysis of the NK-induced proteomic profiles indi-
cates that NK cells may profoundly intervene in the overall
biology of melanoma cells, not only by affecting important
pathways related to tumorigenesis, cell survival/death, and
response to stress, but also by influencing various metabolic
processes.
Transwell experiments indicate that at least some of the NK-
mediated effects are triggered by cell-to-cell interactions but can
be extended to melanoma cells that are not in close contact with
Figure 4.
EMT can increase the suppressive capability of melanoma cells. A, NK cells unconditioned (Nil), conditioned with melanoma cells (Mel), or conditioned
with melanoma cells exposed to EMT cytokines (Mel EMT) were analyzed by FACS for surface expression of the indicated NK receptors. The
conditioning melanoma cell lines are indicated to the left. Histograms represent mean fluorescence intensity (MFI) mean þ SEM of at least four independent
experiments. B, NK cells conditioned as indicated were analyzed for their ability to kill MeDeBO cells in a cytolytic assay. Data represent the mean þ SEM of
6 samples pooled from three independent experiments. Statistical analyses were performed by Wilcoxon t test (A) and Mann–Whitney test (B). Before
phenotypic or functional analyses, NK cells were counted using trypan blue staining to evaluate dead cells. In all conditions analyzed, NK-cell viability
was approximately 90%.
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NK cells, suggesting that NK cells can edit bystander melanoma
cells (i.e., cells that cannot be directly reached and killed). This
effect could be important at the tumor site, where melanoma
cells typically outnumber NK cells.
The NK-mediated tumor cell editing appears to depend, at
least in part, on the engagement of various activating NK
receptors and the release of cytokines, TNFa and, most nota-
bly, IFNg . Along this line, IFNg has been previously suggested
to play a role in several mechanisms of tumor evasion from
NK cells as it enhances the expression of "protective" HLA-I
molecules and induces immunosuppressive mediators such
as IDO (6, 9, 25). In addition, IFNg released by NK cells may
induce autophagy, an event that can protect tumor cells from
both NK- and T-cell attack (32–34). We have analyzed whether
NK cells could promote conversion of cytosolic light chain
3I (LC3I) form in the "autophagic" LC3II form. We did not
observe significant effects in MeDeBO and MeCoP cells (Sup-
plementary Fig. S11), suggesting that in our experimental
system, NK cells may not influence the process of autophagy.
Both cell lines, however, expressed LC3II at baseline. Further
studies on different tumor cells should definitely address
this issue.
Nevertheless, a possible targeting of IFNg in the context of
NK-based therapies must be considered with caution, because
IFNg has also been implicated in different antitumor immune
responses and, notably, in NK-mediated antitumor activity
(35, 36). Further studies aimed at the fine dissection of the
NK:melanoma molecular cross-talk would help to find out
suitable therapeutic targets in this context.
Whatever would be the underlying mechanisms, the NK-
mediated effect on melanoma cells appears to largely overlap
that of the EMT cytokines. Indeed, both NK cells and EMT
cytokines can modify the phenotype of MeDeBO, MeCoP, and
(in part) MeTU while having little effects on MePA and MeTA
cell lines. In line with these findings, MePA and MeTA cells
show no detectable E-cadherin protein expression at baseline
and express N-cadherin, CD271, and CD166 at highest levels
(Fig. 1A; Supplementary Fig. S1), suggesting that they might
have already undergone the phenotype switch to some extent.
The proteomic analysis of two melanoma cell lines exposed to
NK cells or to EMT cytokines confirms that NK cells can
specifically favor the EMT or the tumor phenotype switching,
Figure 5.
Analysis of proteomic profiles induced by NK cells on MeCoP and MeDeBO
cells. A, Venn diagrams indicating the number of proteins modulated by
EMT cytokines, by NK cells or by both stimuli. Differentially expressed
proteins were selected by t test analysis (false discovery rate ¼ 0.05;
S0 ¼ 0.1) of stimulated and unstimulated melanoma cells from three
independent experiments. B, Hierarchical clustering analysis of differentially
expressed proteins in melanoma cells unstimulated (Nil1, 2, 3) or exposed to
NK cells (NK1, 2, 3) in three independent experiments. For these proteins, the
relative expression levels in the EMT cytokine–stimulated melanoma cells for
comparison are also shown. C, Analysis of up- and downregulated protein
enrichment in selected biological processes or pathways (entities). The
enriched entities are grouped according to their affiliation to specific cellular
functions or behaviors. The groups are assigned to wide functional
categories identified by a color code. For each group, the number of entities
enriched in up- or downregulated proteins is indicated in pink and pale blue
(red and blue highlight number of entities >5). The number of selected or
total enriched entities is reported at the bottom.
NK Cells Edit Melanoma Cells: Phenotype Switching and EMT
www.aacrjournals.org Cancer Res; 78(14) July 15, 2018 3921
on July 17, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 11, 2018; DOI: 10.1158/0008-5472.CAN-17-1891 
Figure 6.
IHC analysis of EMT markers and NK-cell infiltrate in melanoma lesions. A, Statistical analysis of E-cadherin, N-cadherin, ZEB1, and ZEB2 expression in
9 "NK-rich" and 13 "NK-poor" melanoma specimens. B, Subserial sections from two primary cutaneous melanoma cases (CASE I: NK-poor – CASE II: NK-rich).
The subserial sections were stained for CD56 (a, b, g, and h), N-cadherin (c, d, i, and l), and E-cadherin (e, f, m, and n) as labeled. For each case,
areas with or without NK cells (NKþ or NK) are shown. Original magnification, 10 (scale bar, 200 mm). C, Statistical analysis of H-score for the expression
of E-cadherin and N-cadherin in the areas "far from NK" and "close to NK." Fields analyzed/condition: n ¼ 10. Statistical analyses were performed by
Mann–Whitney test (A) and Wilcoxon t test (C).
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but also highlights the complexity of the NK-mediated effects
on melanoma cells. As shown in Fig. 5A–C, the NK-induced
proteomic changes largely overlap those induced by EMT
cytokines and involve biological processes or pathways related
to tumor cell transition to aggressive forms. These changes also
include the modulation of proteins involved in several meta-
bolic processes or in cell-cycle regulation, suggesting that NK
cells can contribute to the phenotype switch also through a
general downregulation of tumor cell metabolism and prolif-
eration. Remarkably, these effects may favor the generation of
the so-called "dormant tumor cells" (37), which are thought to
give rise to tumor relapse and metastasis. Finally, both the
analyzed melanoma cell lines show clear increments of proteins
involved in the interaction with immune cells and, in partic-
ular, in the response to IFNg , confirming the pivotal role of this
cytokine in the NK:melanoma cell cross-talk.
The IHC analysis of NK-rich and NK-poor melanoma speci-
mens shows that in NK-rich samples, four EMT markers, includ-
ing E-cadherin, N-cadherin, ZEB1, and ZEB2, were all modu-
lated in the direction of the EMT (although only for E-cadherin
this modulation reached statistical significance). In addition, in
a sample showing heterogeneous cadherin and NK-cell distri-
bution, the modulation of both E- and N-cadherin significantly
correlated with the vicinity of melanoma cells to the local
NK-cell infiltrate. On their complex, the IHC data indicate that
NK cells can effectively participate in the induction of the EMT
at the tumor site. In this context, it should also be considered
that several microenvironmental factors can influence EMT
markers, and veil, in certain circumstances, the effect of NK
cells. In search of EMT markers that could be more specifically
modulated by NK cells, we reevaluated the proteomic data and
noticed that MeDeBO cells exposed to either NK cells or cyto-
kines showed upregulation of SOX5, a transcription factor
involved in the negative regulation of MITF and in the induction
of EMT (see Supplementary Table S1; refs. 38, 39). We analyzed
this molecule in the melanoma lesions and found a clear
statistical correlation between the rich NK-cell infiltrate and the
high expression of SOX5 (Supplementary Fig. S12A and S12B).
In our opinion, this marker deserves further detailed studies to
define its possible role in the NK:tumor cell cross-talk.
MITF downregulation is distinctive of phenotype switch-
ing in melanoma cells. However, the effects of NK cells may
be extended to tumors of epithelial origin, as suggested by the
observation that NK cells can promote the upregulation of two
master regulators of EMT (Supplementary Fig. S3A) and can
induce morphologic changes (compatible with EMT) on the
cervix adenocarcinoma HeLa cell line (Supplementary Fig. S13).
Our data indicate that NK cells promote EMT, but also show
that EMT profoundly influences NK cells. Indeed, EMT can
sharply strengthen the suppressive capability of melanoma cells
by enhancing their ability to induce the downregulation of
important activating receptors on NK cells (Fig. 4A and B).
Some recent studies suggested that the process of EMT plays a
role in different mechanisms of tumor escape. Thus, for exam-
ple, EMT has been shown to induce an immunosuppressive
microenvironment in hepatocellular carcinoma (40), or to
reduce the ability of breast cancer cells to form immunologic
synapses with cytotoxic T lymphocytes (34). On the other
hand, it has also been reported that EMT induction could pro-
mote NKG2D-L upregulation on colorectal cells and on immor-
talized keratinocytes, or induce increased NK cell–mediated
metastasis-specific immunosurveillance in lung cancer (41, 42).
Nevertheless, besides HLA-I molecules, no major NK-receptor
ligands were significantly modified by EMT in our experiments
on melanoma cells (Supplementary Fig. S6), suggesting that a
certain variability among tumor cell types could exist in the
response to EMT stimuli.
In summary, the NK:tumor cell cross-talk in the context of
EMT may occur in melanoma and affect the progression, and
perhaps the fate, of the tumor. This issue opens important
questions on how the tumor microenvironment could influ-
ence the outcome of such "NK:melanoma:EMT" cross-talk.
Indeed, tumor-associated immune and stromal cells, as well
as tumor-associated hypoxia, are known to favor EMT (19)
and/or modulate NK-cell function (6, 7). Additional questions
regard the type and the functional status of the NK cells that
participate in the cross-talk at the tumor site. Conventional
CD56dimCD16bright NK cells have been reported to infiltrate
tumor tissues in several solid tumors (18, 43). Tissue
CD56dimCD16bright cells generally lack markers of tissue-resi-
dent lymphocytes (i.e., CD69, CD103, or CD49a) and are
considered as cells recirculating from peripheral blood
(44, 45), where, indeed, CD56dimCD16bright cells are largely
represented. Along this line, peripheral blood–derived NK cells
have been recently shown to migrate in response to chemo-
tactic stimuli released during NK:melanoma cell interaction
(46). Intriguingly, tumor tissues are also frequently infiltrated
by cells expressing the CD56brightCD16dim phenotype (47).
These cells constitute a small fraction of circulating NK cells
but are well represented in certain tissues or secondary lym-
phoid organs (44, 47). CD56brightCD16dim cells are character-
ized by low cytotoxicity and high IFNg production in response
to cytokines; hence, they may have a different, even more
pronounced, effect on tumor phenotype switch and EMT.
Thus, our data on PBNK cells offer reliable hints to characterize
the NK:tumor cell cross-talk, at least for tumors showing the
CD56dimCD16bright NK-cell infiltrate. Further studies involving
specific NK-cell subsets and dissecting the effect of specific
components of the tumor microenvironment would integrate
and extend our data and provide important clues to design
personalized and hopefully effective NK-based therapies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Authors' Contributions
Conception and design: L. Huergo-Zapico, E.J. DeAndres-Galiana,
A. Lopez-Soto, L. Moretta, S. Gonzalez, M. Vitale
Development of methodology: L. Huergo-Zapico, J.L. Fernandez-Martínez,
E.J. DeAndres-Galiana
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): L.Huergo-Zapico,C.Cantoni, C. Lavarello, A. Petretto,
G. Pietra, M. Bugatti, E. Munari, M. Marconi, W. Vermi, L. Moretta
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): L. Huergo-Zapico, M. Parodi, C. Cantoni,
C. Lavarello, J.L. Fernandez-Martínez, A. Petretto, E.J. DeAndres-Galiana,
M. Balsamo, A. Lopez-Soto, G. Pietra, M. Bugatti, E. Munari, W. Vermi,
L. Moretta, S. Gonzalez, M. Vitale
Writing, review, and/or revision of the manuscript: L. Huergo-Zapico,
M. Parodi, C. Cantoni, J.L. Fernandez-Martínez, E.J. DeAndres-Galiana,
A. Lopez-Soto, M.C. Mingari, L. Moretta, S. Gonzalez, M. Vitale
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): L. Huergo-Zapico
Study supervision: L. Huergo-Zapico, L. Moretta, M. Vitale
NK Cells Edit Melanoma Cells: Phenotype Switching and EMT
www.aacrjournals.org Cancer Res; 78(14) July 15, 2018 3923
on July 17, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 11, 2018; DOI: 10.1158/0008-5472.CAN-17-1891 
Acknowledgments
This work was supported by grants awarded by Associazione Italiana
Ricerca sul Cancro AIRC: IG 2014 project n. 15428 (to M. Vitale), IG 2014
project n. 15283 (to L. Moretta), IG 2014 project n. 15378 (to W. Vermi),
and "Special Program Molecular Clinical Oncology 5  100000 project
n. 9962 (to L. Moretta); PRA 2013 and FRA 2015, DIMES, University of
Genoa (to G. Pietra); 5  1000 Min. Sal. 2014 and 2015 (5M-2014-
2353563 and 5M-2015-2360333 to M. Vitale and M.C. Mingari); the
Spanish grants of Instituto de Salud Carlos III (PI16/01485), and FEDER
European Union (to S. Gonzalez). M. Parodi was recipient of the AIRC
fellowship n. 18274, year 2016. L. Huergo-Zapico was recipient of the
EMBO short-term fellowship ASTF 520 - 2012. M. Bugatti is supported by
Fondazione Beretta (Brescia, Italy).
Received June 26, 2017; revised December 19, 2017; accepted May 8, 2018;
published first May 11, 2018.
References
1. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, et al.
Cellular and molecular basis of haploidentical hematopoietic stem cell
transplantation in the successful treatment of high-risk leukemias: role of
alloreactive NK cells. Front Immunol 2013;4:15.
2. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of
autologous natural killer cells leads to high levels of circulating natural
killer cells but does not mediate tumor regression. Clin Cancer Res
2011;17:6287–97.
3. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural
killer cells in cancer therapy and transplantation. Semin Immunol 2014;
26:161–72.
4. Cantoni C, Grauwet K, Pietra G, Parodi M, Mingari MC, Maria AD, et al.
Role of NK cells in immunotherapy and virotherapy of solid tumors.
Immunotherapy 2015;7:861–82.
5. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in
cancer immunotherapy. Nat Immunol 2016;17:1025–36.
6. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells
and tumor microenvironment on NK-cell function. Eur J Immunol
2014;44:1582–92.
7. Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity.
Immunobiology 2017;222:11–20.
8. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al.
Innate or adaptive immunity? The example of natural killer cells. Science
2011;331:44–9.
9. Balsamo M, Vermi W, Parodi M, Pietra G, Manzini C, Queirolo P, et al.
Melanoma cells become resistant to NK-cell-mediated killing when
exposed to NK-cell numbers compatible with NK-cell infiltration in the
tumor. Eur J Immunol 2012;42:1833–42.
10. Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, Lopez-Diaz de Cerio A,
Cabo M, et al. Targeting NK-cell checkpoints for cancer immunotherapy.
Curr Opin Immunol 2017;45:73–81.
11. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yama-
guchi K, et al. IFN-gamma from lymphocytes induces PD-L1 expression
andpromotes progressionof ovarian cancer. Br JCancer 2015;112:1501–9.
12. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al.
Identificationof a subset of humannatural killer cells expressinghigh levels
of programmed death 1: A phenotypic and functional characterization.
J Allergy Clin Immunol 2017;139:335–46.
13. Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, et al. The
immune checkpoint ligand PD-L1 is upregulated in EMT-activated human
breast cancer cells by amechanism involving ZEB-1 andmiR-200.Oncoim-
munology 2017;6:e1263412.
14. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal
transition and dissemination of cancer cells is driven by myeloid-derived
suppressor cells infiltrating the primary tumor. PLoS Biol 2011;9:
e1001162.
15. Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao L, et al. Tumor-associated
macrophages promote cancer stem cell-like properties via transforming
growth factor-beta1-induced epithelial-mesenchymal transition in hepa-
tocellular carcinoma. Cancer Lett 2014;352:160–8.
16. Mayer C, Darb-Esfahani S, Meyer AS, Hubner K, Rom J, Sohn C, et al.
Neutrophil granulocytes in ovarian cancer - induction of epithelial-to-
mesenchymal-transition and tumor cell migration. J Cancer 2016;7:
546–54.
17. Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L,
et al. CD4þ T cells potently induce epithelial-mesenchymal-transition
in premalignant and malignant pancreatic ductal epithelial cells-novel
implications of CD4þ T cells in pancreatic cancer development.
Oncoimmunology 2015;4:e1000083.
18. Cantoni C, Huergo-Zapico L, Parodi M, Pedrazzi M, Mingari MC, Moretta
A, et al. NK cells, tumor cell transition, and tumor progression in solid
malignancies: new hints for NK-based immunotherapy? J Immunol Res
2016;2016:4684268.
19. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nat Rev Cancer
2009;9:265–73.
20. Kemper K, de Goeje PL, Peeper DS, van Amerongen R. Phenotype switch-
ing: tumor cell plasticity as a resistance mechanism and target for therapy.
Cancer Res 2014;74:5937–41.
21. Fukunaga-Kalabis M, Roesch A, HerlynM. From cancer stem cells to tumor
maintenance in melanoma. J Invest Dermatol 2011;131:1600–4.
22. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M,
Willems PH, et al. Activated leukocyte cell adhesion molecule (ALCAM/
CD166/MEMD), a novel actor in invasive growth, controls matrix metal-
loproteinase activity. Cancer Res 2005;65:8801–8.
23. Mikesh LM, Kumar M, Erdag G, Hogan KT, Molhoek KR, Mayo MW, et al.
Evaluation of molecular markers of mesenchymal phenotype in melano-
ma. Melanoma Res 2010;20:485–95.
24. Boiko AD, RazorenovaOV, van de RijnM, Swetter SM, JohnsonDL, Ly DP,
et al. Human melanoma-initiating cells express neural crest nerve growth
factor receptor CD271. Nature 2010;466:133–7.
25. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al.
Melanoma cells inhibit natural killer cell function by modulating the
expression of activating receptors and cytolytic activity. Cancer Res 2012;
72:1407–15.
26. Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M. Minimal, encapsulated
proteomic-sample processing applied to copy-number estimation in
eukaryotic cells. Nat Methods 2014;11:319–24.
27. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The
Perseus computational platform for comprehensive analysis of (prote)
omics data. Nat Methods 2016;13:731–40.
28. Saligan LN, Fernandez-Martinez JL, deAndres-Galiana EJ, Sonis S. Super-
vised classification by filter methods and recursive feature elimination
predicts risk of radiotherapy-related fatigue in patients with prostate
cancer. Cancer Informat 2014;13:141–52.
29. deAndres-Galiana EJ, Fernandez-Martinez JL, Sonis ST. Design of Biomed-
ical Robots for Phenotype Prediction Problems. J Comput Biol
2016;23:678–92.
30. Xu L, BegumS,Hearn JD,Hynes RO.GPR56, an atypicalGprotein-coupled
receptor, binds tissue transglutaminase, TG2, and inhibits melanoma
tumor growth and metastasis. Proc Natl Acad Sci U S A 2006;103:
9023–8.
31. SeoH, Jeon I, KimBS, ParkM, Bae EA, Song B, et al. IL-21-mediated reversal
of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-
deficient tumours. Nat Commun 2017;8:15776.
32. Buchser WJ, Laskow TC, Pavlik PJ, Lin HM, Lotze MT. Cell-mediated
autophagy promotes cancer cell survival. Cancer Res 2012;72:
2970–9.
33. Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, et al.
Granzyme B degradation by autophagy decreases tumor cell susceptibility
to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A
2013;110:17450–5.
34. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, et al.
Epithelial-to-mesenchymal transition and autophagy induction in breast
carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013;
73:2418–27.
35. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, et al.
Natural killer cell IFN-gamma levels predict long-term survival with
Huergo-Zapico et al.
Cancer Res; 78(14) July 15, 2018 Cancer Research3924
on July 17, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 11, 2018; DOI: 10.1158/0008-5472.CAN-17-1891 
imatinib mesylate therapy in gastrointestinal stromal tumor-bearing
patients. Cancer Res 2009;69:3563–9.
36. Tu TC, Brown NK, Kim TJ, Wroblewska J, Yang X, Guo X, et al. CD160 is
essential for NK-mediated IFN-gamma production. J Exp Med 2015;212:
415–29.
37. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated
cancer cell dormancy: an awakening field. Nat Rev Cancer 2014;14:
611–22.
38. Kordass T, Weber CE, Oswald M, Ast V, Bernhardt M, Novak D, et al. SOX5
is involved in balanced MITF regulation in human melanoma cells.
BMC Med Genet 2016;9:10.
39. Wang D, Han S, Wang X, Peng R, Li X. SOX5 promotes epithelial-
mesenchymal transition and cell invasion via regulation of Twist1 in
hepatocellular carcinoma. Med Oncol 2015;32:461.
40. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, et al. Hypoxia-induced
epithelial-to-mesenchymal transition in hepatocellular carcinoma induces
an immunosuppressive tumor microenvironment to promote metastasis.
Cancer Res 2016;76:818–30.
41. Lopez-Soto A, Huergo-Zapico L, Galvan JA, Rodrigo L, de Herreros AG,
Astudillo A, et al. Epithelial-mesenchymal transition induces an antitumor
immune response mediated by NKG2D receptor. J Immunol 2013;190:
4408–19.
42. Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG.
Epithelial-mesenchymal transition leads to NK cell-mediated metasta-
sis-specific immunosurveillance in lung cancer. J Clin Invest 2018;128:
1384–96.
43. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P,
et al. Profound coordinated alterations of intratumoral NK cell phenotype
and function in lung carcinoma. Cancer Res 2011;71:5412–22.
44. Bjorkstrom NK, Ljunggren HG, Michaelsson J. Emerging insights into
natural killer cells in human peripheral tissues. Nat Rev Immunol 2016;
16:310–20.
45. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of
human natural killer cell diversity. Immunity 2017;47:820–33.
46. Parodi M, Pedrazzi M, Cantoni C, AvernaM, PatroneM, Cavaletto M, et al.
Natural Killer (NK)/melanoma cell interaction induces NK-mediated
release of chemotactic High Mobility Group Box-1 (HMGB1) capable
of amplifying NK cell recruitment. Oncoimmunology 2015;4:e1052353.
47. Carrega P, Ferlazzo G. Natural killers are made not born: how to exploit
NK cells in lung malignancies. Front Immunol 2017;8:277.
www.aacrjournals.org Cancer Res; 78(14) July 15, 2018 3925
NK Cells Edit Melanoma Cells: Phenotype Switching and EMT
on July 17, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 11, 2018; DOI: 10.1158/0008-5472.CAN-17-1891 
2018;78:3913-3925. Published OnlineFirst May 11, 2018.Cancer Res 
  
Leticía Huergo-Zapico, Monica Parodi, Claudia Cantoni, et al. 
  
Phenotypic and Proteomic Changes in Melanoma Cell Lines



































Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/78/14/3913
To request permission to re-use all or part of this article, use this link
on July 17, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 11, 2018; DOI: 10.1158/0008-5472.CAN-17-1891 
